• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears CT-Based AI Software for Assessing Interstitial Lung Disease

News
Article

Reportedly trained on thousands of computed tomography scans, the e-Lung software utilizes machine learning to detect and assess the progression of features associated with interstitial lung diseases.

The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence-powered e-Lung software, which may enhance assessment for interstitial lung disease (ILD) on computed tomography (CT) scans.1

Incorporating evaluation of vascular structures in the periphery of the lung and reticular opacities, the e-Lung software provides a weighted reticulovascular score (WRVS) that quantifies key contributing factors for ILDs, according to Brainomix, the developer of the e-Lung software.1,2

FDA Clears CT-Based AI Software for Assessing Interstitial Lung Disease

In recent research, published in the Journal of Respiratory and Critical Care Medicine, researchers found that an e-Lung WRVS threshold of > 15 percent was associated with a greater than fivefold risk of forced vital capacity (FVC) decline. The AI-powered e-Lung software was recentlly granted 510(k) clearance from the FDA. (Image courtesy of Brainomix.)

In recent research, published in the Journal of Respiratory and Critical Care Medicine, researchers found that an e-Lung WRVS threshold of > 15 percent was associated with a greater than fivefold risk of forced vital capacity (FVC) decline.2 The study authors also noted that at 52 weeks, WRVS assessment had a 16 percent higher C-index for identifying FVC decline in comparison to conventional FVC assessment (77 percent vs. 61 percent).2

“The preliminary data for e-Lung is impressive and would indicate that we have a promising tool that could help to expedite healthcare delivery and improve clinically meaningful outcomes for patients with lung disease,” noted Deji Adegunsoye, M.D., an assistant professor of medicine and scientific director of the Interstitial Lung Disease Program at the University of Chicago Medicine.

References

1. Brainomix. Brainomix achieves breakthrough with FDA clearance of e-Lung AI software. PR Newswire. Available at: https://www.prnewswire.com/news-releases/brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software-302144832.html . Published May 17, 2024. Accessed May 17, 2024.

2. Devaraj A, Ottink F, Rennison-Jones C, et al. E-Lung computed tomography biomarker stratifies patients at risk of idiopathic pulmonary fibrosis progression in a 52-week clinical trial. Am J Respir Crit Care Med. 2024;209(9):1168-1169.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.